Evommune, Inc.
EVMNDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
EVMN Earnings Report
EPS Est: $-0.68 | FQ end 2026-06
How EVMN's past catalysts played out
EVO101
Atopic Dermatitis Eczema
Oral EVO756
Chronic Inducible Urticaria
EVO756
Chronic Spontaneous Urticaria
EVO301
Atopic Dermatitis (AD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EVO101 | Phase 2 | Atopic Dermatitis Eczema | - | - |
Oral EVO756 | Phase 2 | Chronic Inducible Urticaria | - | - |
EVO756 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
EVO301 | Phase 2 | Atopic Dermatitis (AD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Evommune, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Evommune, Inc.'s (EVMN) pipeline across Phase 2. Its lead program is EVO101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Evommune, Inc.'s next FDA catalyst?→
Evommune, Inc.'s (EVMN) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EVMN biotech catalysts?→
Add EVMN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evommune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.